Compare Realty Income Corp (O) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Realty Income Corp trades at $60.35 (market cap $57.74B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: Realty Income Corp pays a 5.33% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Realty Income Corp nearer its low. Which is the better fit depends on your goals.
| O | XBI | |
|---|---|---|
Market Cap | $57.74B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $67.56 | $169.55 |
52-Week Low | $55.93 | $93.43 |
Enterprise Value | $88.37B | — |
Dividend Yield | 5.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $61.02, down 0.38% on the day, with a bearish technical signal from moving averages. The stock has missed earnings expectations for the last three quarters, but revenue grew to $5.75B in 2025 with a net income margin of 21.23%. Recent news highlights the company's 136th consecutive monthly dividend increase to $0.2715 per share, underscoring its income-focused appeal amid a 5.3% yield.
The outlook is mixed: analyst consensus leans hold with a $66.50 price target, suggesting modest upside, but rising debt levels and interest rate sensitivity pose risks. Earnings misses and a high P/E of 44.54 indicate valuation concerns, though dividend growth and high occupancy support income stability for long-term investors.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
